Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Axon Enterprise Inc (AXON) vs Becton Dickinson and Co (BDX) Price & Performance

Axon Enterprise IncTrade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

Axon Enterprise Inc vs Becton Dickinson and Co — how do they compare? Axon Enterprise Inc trades at $604.5 (market cap $51.69B), while Becton Dickinson and Co trades at $180.72 (market cap $49.41B). The key difference: Axon Enterprise Inc and Becton Dickinson and Co are close in size by market cap, and Becton Dickinson and Co pays a 2.32% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.

AXONBDX
Market Cap
$51.69B$49.41B
Sector
TechnologyHealth
52-Week High
$791.62$185.39
52-Week Low
$345.94$138.62
Enterprise Value
$52.83B$65.51B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Axon Enterprise Inc

Axon Enterprise (AXON) trades at $616.97, up 3.46% in the last 24 hours, showing strong momentum with a bullish technical signal and consistent earnings beats. The stock is near its pivot point of $629, with support at $616 and resistance at $649. Revenue grew 35% year-over-year in Q2 2026, driven by AI and counter-drone offerings, though high valuation multiples like a P/E of 265.13 and P/S of 16.35 reflect premium pricing. Analyst consensus is strongly bullish with an $685 price target, but gross margin compression and elevated multiples pose risks.

Outlook remains positive given robust growth and AI adoption, but investors face valuation risks and margin pressures. The stock offers upside to consensus targets if execution continues, yet any growth slowdown could trigger significant multiple contraction. Key catalysts include Q3 2026 earnings and AI-driven contract expansions.

Becton Dickinson and Co

BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.

The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Axon Enterprise Inc

Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.

Read more on AXON

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX